Phase 2 × Sarcoma, Alveolar Soft Part × Clear all
NCT02867592 2026-04-13

Cabozantinib-S-Malate in Treating Younger Patients With Recurrent, Refractory, or Newly Diagnosed Sarcomas, Wilms Tumor, or Other Rare Tumors

National Cancer Institute (NCI)

Phase 2 Active not recruiting
109 enrolled 24 charts
NCT00112463 2017-06-14

Depsipeptide (Romidepsin) in Treating Patients With Metastatic or Unresectable Soft Tissue Sarcoma

National Cancer Institute (NCI)

Phase 2 Completed
40 enrolled 11 charts
NCT00474994 2016-01-20

Sunitinib in Treating Patients With Metastatic, Locally Advanced, or Locally Recurrent Sarcomas

Memorial Sloan Kettering Cancer Center

Phase 2 Completed
53 enrolled 6 charts
NCT00003718 2014-01-06

Temozolomide in Treating Patients With Advanced Soft Tissue Sarcoma

National Cancer Institute (NCI)

Phase 2 Unknown
25 enrolled
NCT00526149 2013-10-07

BI 2536 in Treating Patients With Recurrent or Metastatic Solid Tumors

European Organisation for Research and Treatment of Cancer - EORTC

Phase 2 Completed
76 enrolled
NCT00003939 2012-09-24

Ecteinascidin 743 in Treating Patients With Advanced Soft Tissue Sarcoma

European Organisation for Research and Treatment of Cancer - EORTC

Phase 2 Completed
132 enrolled